Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Addition of capivasertib to fulvestrant doubles progression-free survival in HR-positive breast cancer patients
In patients with hormone receptor (HR)-positive, HER2-negative tumors resistant to aromatase inhibitors, addition of the investigational AKT inhibitor capivasertib to fulvestrant (Faslodex) doubled the median progression-free survival compared with placebo plus fulvestrant in the phase III CAPItello-291 clinical trial, according…
